Literature DB >> 3286384

Continuous intravenous infusions of famotidine maintain high intragastric pH in duodenal ulcer.

H S Merki1, L Witzel, D Kaufman, M Kempf, J Neumann, J Röhmel, R P Walt.   

Abstract

Three double blind crossover studies were carried out to assess the ability of primed infusions of famotidine to raise intragastric pH over 24 hours in 12 duodenal ulcer patients. pH was measured continuously using intragastric electrodes and solid state recording devices. The studies compared the effects of placebo, famotidine 10 mg bolus injection iv followed by continuous infusions of 3.2 mg/h and 4 mg/h in random order. Gastric acidity decreased significantly with both dose regimens (p less than 0.0005) but the effects of either dosage were similar. During fasting median pH rose from 1.35 to 7.1 and 7.05 respectively. During the day, when standard meals were taken, median pH rose from 1.30 to 4.3 and 3.65 respectively. Despite continuous infusions the H2-antagonist was less effective during this time. The latter finding raises questions about gastric secretory control during the day when food is eaten.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3286384      PMCID: PMC1433542          DOI: 10.1136/gut.29.4.453

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  24 in total

1.  Evaluation of intragastric pH in acutely ill patients.

Authors:  V Herrmann; D L Kaminski
Journal:  Arch Surg       Date:  1979-04

2.  Antacid titration in the prevention of acute gastrointestinal bleeding: a controlled, randomized trial in 100 critically ill patients.

Authors:  P R Hastings; J J Skillman; L S Bushnell; W Silen
Journal:  N Engl J Med       Date:  1978-05-11       Impact factor: 91.245

3.  Comparison of ranitidine 300 mg twice daily, 300 mg at night and placebo on 24-hour intragastric acidity of duodenal ulcer patients.

Authors:  H S Merki; L Witzel; R P Walt; J Neumann; E Scheurle; D Kaufmann; A Mappes; J Heim; J Röhmel
Journal:  Aliment Pharmacol Ther       Date:  1987-06       Impact factor: 8.171

4.  The prevention of upper gastrointestinal tract bleeding in patients in an intensive care unit.

Authors:  M J Zinner; G D Zuidema; M Mignosa
Journal:  Surg Gynecol Obstet       Date:  1981-08

5.  Cimetidine in bleeding peptic ulcer.

Authors:  A M Hoare; G V Bradby; C F Hawkins; J Y Kang; P W Dykes
Journal:  Lancet       Date:  1979-09-29       Impact factor: 79.321

6.  Complete inhibition of food-stimulated gastric acid secretion by combined application of pirenzepine and ranitidine.

Authors:  W Londong; V Londong; C Ruthe; P Weizert
Journal:  Gut       Date:  1981-07       Impact factor: 23.059

7.  24-hour control of intragastric acidity by cimetidine in duodenal-ulcer patients.

Authors:  R E Pounder; J G Williams; G J Milton-Thompson; J J Misiewicz
Journal:  Lancet       Date:  1975-11-29       Impact factor: 79.321

8.  Antacid versus cimetidine in preventing acute gastrointestinal bleeding. A randomized trial in 75 critically ill patients.

Authors:  H J Priebe; J J Skillman; L S Bushnell; P C Long; W Silen
Journal:  N Engl J Med       Date:  1980-02-21       Impact factor: 91.245

9.  Inhibition of pentagastrin-stimulated and nocturnal gastric secretion by ranitidine. A new H2-receptor antagonist.

Authors:  N R Peden; J H Saunders; K G Wormsley
Journal:  Lancet       Date:  1979-03-31       Impact factor: 79.321

10.  Comparison of the effects of ranitidine, cimetidine and placebo on the 24 hour intragastric acidity and nocturnal acid secretion in patients with duodenal ulcer.

Authors:  R P Walt; P J Male; J Rawlings; R H Hunt; G J Milton-Thompson; J J Misiewicz
Journal:  Gut       Date:  1981-01       Impact factor: 23.059

View more
  11 in total

1.  Effects of famotidine on upper gastrointestinal motility in patients with progressive systemic sclerosis.

Authors:  T Horikoshi; T Sekiguchi; M Kusano; T Matsuzaki
Journal:  Gastroenterol Jpn       Date:  1991-04

2.  Effect of food on H2-receptor blockade in normal subjects and duodenal ulcer patients.

Authors:  H S Merki; F Halter; C Wilder-Smith; P Allemann; L Witzel; M Kempf; J Roehmel; R P Walt
Journal:  Gut       Date:  1990-02       Impact factor: 23.059

3.  Rebound nocturnal hypersecretion after H2-receptor antagonist.

Authors:  V Savarino; G S Mela
Journal:  Gut       Date:  1989-09       Impact factor: 23.059

Review 4.  Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  H D Langtry; S M Grant; K L Goa
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

5.  Clot lysis by gastric juice: an in vitro study.

Authors:  S E Patchett; H Enright; N Afdhal; W O'Connell; D P O'Donoghue
Journal:  Gut       Date:  1989-12       Impact factor: 23.059

6.  Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study.

Authors:  J Labenz; U Peitz; C Leusing; B Tillenburg; A L Blum; G Börsch
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

7.  Use of automatic computerised pump to maintain constant intragastric pH.

Authors:  A Hannan; I Chesner; H S Merki; S Mann; R P Walt
Journal:  Gut       Date:  1990-11       Impact factor: 23.059

8.  Low bedtime doses of H2-receptor antagonists for acute treatment of duodenal ulcer.

Authors:  V Savarino; G S Mela; P Zentilin; G Bonifacino; M Moretti; F Valle; G Celle
Journal:  Dig Dis Sci       Date:  1989-07       Impact factor: 3.199

Review 9.  Current management of bleeding peptic ulcer. A review.

Authors:  M Z Panos; R P Walt
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

10.  Maintenance of intragastric pH > 4 with famotidine in duodenal ulcer patients: factors influencing drug requirements.

Authors:  J C Delchier; F Roudot-Thoraval; L Stanescu; M C Deharvengt; L Elouaer Blanc
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.